Skip to main content
PMC home page
PLOS ONE logoLink to PLOS ONE
. 2018 Aug 16;13(8):e0202667. doi: 10.1371/journal.pone.0202667

The VP1 unique region of human parvovirus B19 and human bocavirus induce lung injury in naïve Balb/c mice

Chun-Yu Lin 1,2, Yu-Han Chung 3, Ya-Fang Shi 3, Bor-Show Tzang 3,4,5,6,*, Tsai-Ching Hsu 3,5,6,*
Editor: Jianming Qiu7
PMCID: PMC6095614  PMID: 30114253

Abstract

Both human parvovirus B19 (B19V) and human bocavirus (HBoV) are known to be important human pathogens of the Parvoviridae family. Our earlier investigation demonstrated that both B19V-VP1u and HBoV-VP1u have a significantly disruptive effect on tight junctions (TJs) in A549 cells, implying the essential role of parvovirus in airway infection and lung injury. However, no direct evidence that B19V-VP1u and HBoV-VP1u induce lung injury exists. The present study further investigates the induction of lung injury by B19V-VP1u and HBoV-VP1u in naïve Balb/c mice following subcutaneous injection of PBS, recombinant B19V-VP1u or HBoV-VP1u. The experimental results reveal significantly increased activity, protein expression and ratio of matrix metalloproteinase-9 (MMP-9) to MMP-2 in Balb/c mice that received B19V-VP1u or HBoV-VP1u compared to those that received PBS. Significantly higher levels of inflammatory cytokines, including IL-6 and IL-1β, and greater lymphocyte infiltration in lung tissue sections were detected in mice that received B19V-VP1u or HBoV-VP1u. Additionally, significantly increased levels of phosphorylated p65 (NF-κB) and MAPK signaling proteins were observed in lung tissue of mice that received B19V-VP1u or HBoV-VP1u compared to those of mice that received PBS. These findings demonstrate for the first time that B19V-VP1u and HBoV-VP1u proteins induce lung inflammatory reactions through p65 (NF-κB) and MAPK signaling.

Introduction

A growing body of evidence has implicated viral respiratory tract infection a predominant risk factor associated with a variety of lung illnesses, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis (CF) [1]. Infection with viruses, such as rhinovirus, influenza and respiratory syncytial virus (RSV), has been indicated as an important contributor to COPD exacerbations in 40% to 60% of all COPD patients [2]. Other longitudinal investigations have reported that episodes of rhinovirus- or RSV-infection resemble manifestations of asthma, especially in younger groups, and are related to the later development of asthma [3–5]. RSV infection accounts for up to one-third of hospitalizations, respiratory failure, and the chronic supplemental oxygen requirement of infants with cystic fibrosis (CF). Similar results have been obtained for children with CF who have impaired lung function [6–9].

The human parvovirus B19V (B19V) and human bocavirus (HBoV) are members of the Parvoviridae family known to be two important parvoviruses that are responsible for many human diseases [10–13]. The VP1 unique region (VP1u) of both B19V and HBoV has the motif and activity of secreted phospholipidase (sPLA2) which has been demonstrated to have an essential role in infectivity and induction of inflammation in host cells [14–16]. Notably, B19V and HBoV are also respiratory viruses, which can be transmitted through respiratory tract infection and are strongly associated with the development of various respiratory diseases such as sinusitis, pharyngitis, obstructive bronchitis, bronchopneumonia and asthma [17–21]. These findings reveal that parvoviruses have a critical role in airway infection and the development of lung disease.

Although previous studies have suggested a connection between parvovirus infection and lung disease [22–23], no direct evidence of this connection has been reported. Our recent study revealed that HBoV-VP1u and B19V-VP1u have a significantly disruptive effect on tight junctions (TJs) in A549 lung cells [24]. Accordingly, the current study further investigates the induction of lung injury by B19V-VP1u and HBoV-VP1u in naïve mice following subcutaneous injection of recombinant B19V-VP1u and HBoV-VP1u proteins, with the goal of clarifying the potential involvement of human parvoviruses in the induction of lung disease.

Materials and methods

Preparation of recombinant human B19V-VP1u, HBoV-VP1u, B19V-VP1uD175A and HBoV-VP1uL48R proteins

DNA fragments encompassing B19V-VP1u, B19V-VP1uD175A [25], HBoV-VP1u [24] (TW125_07: GeneBank accession number EU984241.1, provided by Centers for Disease Control, Taipei, Taiwan) and HBoV-VP1uL48R [26] were amplified by polymerase chain reaction (PCR). The DNA fragments of B19V-VP1u, B19V-VP1uD175A, HBoV-VP1u and HBoV-VP1uL48R were then separately ligated into pET-32a vector (Novagene, Cambridge, MA). The products of ligations, pET32a-B19V-VP1u, pET32a-B19V-VP1uD175A, pET32a-HBoV-VP1u and pET32a-HBoV-VP1uL48R, were then transformed into Escherichia coli BL21-DE3 competent cells (Invitrogen, Carlsbad, CA). The B19V-VP1u, B19V-VP1uD175A, HBoV-VP1u and HBoV-VP1uL48R recombinant proteins were expressed by inducing with IPTG (1 mM) and purified with a Ni-NTA spin column (Qiagen, Chatsworth, CA, USA) and PureProteome™ Nickel Magnetic Beads (EMD Millipore, CA, USA). The bvPLA2 was used as positive control that exhibits the PLA2 catalytic activity of 0.430±0.016 μmol/min/mL. Two μg B19V-VP1u and HBoV-VP1u recombinant proteins were analyzed to measure their sPLA2 activity that exhibits 0.386±0.015 μmol/min/mL and 0.564±0.032 μmol/min/mL, respectively. No sPLA2 activity was detected in recombinant B19V-VP1uD175A and HBoV-VP1uL48R proteins.

Ethics and animals

Fifteen female BALB/c mice aged 6 weeks were purchased from the National Laboratory Animal Center, Taiwan. Approval for this study was obtained from the Institutional Animal Care and Use Committee of Chung Shan Medical University, Taichung, Taiwan (No. 1241). The animals were kept under a 12-h light-dark cycle and ambient temperature was maintained at 25°C. Animals were allowed free access to water and standard laboratory chow (Lab Diet 5001; PMI Nutrition International Inc., Brentwood, MO, USA). At the age of 8 weeks, all mice were randomly divided into three groups (five mice per group) and injected subcutaneously with 20 μg purified B19V-VP1u or HBoV-VP1u recombinant proteins or phosphate-buffered saline (PBS) mixed 1:1 (v/v) with Freund's complete adjuvant (Sigma-Aldrich, UK). The mice were boosted with 10 μg B19V-VP1u and HBoV-VP1u recombinant proteins or phosphate-buffered saline (PBS) mixed 1:1 (v/v) with Freund's incomplete adjuvant (Sigma-Aldrich, UK) every two weeks for 3 times and then sacrificed at the age of 16 weeks by CO2 asphyxiation. The heart blood and lung tissues were collected and stored at −80°C until use.

Hematoxylin-eosin staining

The lung samples of animals were excised and soaked in formalin and covered with wax. The section slides were prepared by deparaffinization and dehydration and were passed through a series of graded alcohols (100%, 95% and 75%) for 15 min each. The slides were then dyed with hematoxylin. After gently rinsing with water, each slide was then soaked with 85% alcohol, 100% alcohol I and II for 15 min each. Finally, they were soaked with Xylene I and Xylene II. Photomicrographs were obtained using Zeiss Axiophot microscopes. For quantification, the number of infiltrated lymphocytes was counted in 4 randomly selected fields of a section slide. All measurements were made using at least 3 section slides from 3 independent animals.

Preparation of tissue extract and immunoblotting

All procedures were performed at 4°C in a cold room. The lung tissue samples obtained from Balb/c mice were homogenized in 600 μl PRO-PREP™ solution (iNtRON Biotech, Korea) by 30 strokes using a Dounce Homogenizer (Knotes Glass, Vineland, NJ). The homogenates were centrifuged at 13,000 rpm for 10 min at 4°C, and the supernatant was then stored at −80°C until use. Protein concentration of tissue extracts was determined using bovine serum albumin as a standard and immunoblotting was performed as described previously [24]. Briefly, equal amount of protein samples (25μg per sample) were separated in a 10% or 12.5% SDS-PAGE and electrophoretically transferred to nitrocellulose (NC) membrane (Amersham Biosciences, Piscataway, NJ, USA). After blocking with 5% non-fat dry milk in PBS, antibodies against MMP9, MMP2, IL-6, IL-1β, NF-κB (p65), p-P38, p-JNK, p-ERK, (Santa Cruz Biotechnology, CA, USA) and β-actin (MAB1501, Chemicon; EMD Millipore, Temecula, CA, USA) were diluted in PBS with 2.5% BSA and incubated with NC membrane for 1.5h. The membranes were then washed twice with PBS-Tween for 1 h and reacted with secondary antibody conjugated with horseradish peroxidase (HRP) (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Immobilon Western HRP Chemiluminescent Substrate (EMD Millipore) was used to detect the antigen-antibody complexes. The blots were scanned and quantified by a densitometry apparatus (Alpha-Imager 2200; ProteinSimple, San Jose, CA, USA).

Gel zymography

The activities of matrix metalloproteinase-2 (MMP2) and matrix metalloproteinase-9 (MMP9) were analyzed by gelatin zymography assays as described previously [26]. Briefly, 25 μg lung tissue lysates from Balb/c mice were separated on a 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel containing 0.1% gelatin. The gels were washed for 30 min in 2.5% Triton X-100 and then soaked in the reaction buffer (40 mM Tris–HCl, pH 8.0, 10 mM CaCl2 and 0.02% NaN3) for 16 h. Gelatinolytic activity was visualized by staining the gels with 0.5% Coomassie brilliant blue R-250, destained with methanol–acetic acid water. Relative MMP levels were quantified by a gel documentation and analysis system (Alpha-Imager 2200; ProteinSimple, San Jose, CA, USA).

Statistical analysis

All statistical analyses were performed using GraphPad Prism 5 software (GraphPad Software, CA) by one-way analysis of variance (One-way ANOVA) followed by Tukey multiple-comparisons test. Data were represented as the mean ± SEM and verified by at least three independent experiments. A value of P < 0.05 was considered statistically significant. Significant differences are indicated with a star symbol, as shown in the figures.

Results

B19V-VP1u and HBoV-VP1u proteins increase activity and expression of MMP-9 and MMP-2 in lung tissue of Balb/c mice

Elevated MMP-9 and MMP-2 activities have been linked to numerous lung disorders. To determine whether B19V-VP1u and HBoV-VP1u proteins cause lung injury in Balb/c mice, the activities and expressions of MMP-9 and MMP-2 were detected. Significantly increased activities of MMP-9 and MMP-2 were observed in lung tissue from Balb/c mice that received B19V-VP1u or HBoV-VP1u protein than in those mice that received PBS (Fig 1A). Fig 1B and 1C display quantitative results concerning MMP-9 and MMP-2 activities. Fig 1D displays the activity ratio of MMP-9 to MMP-2. The levels of MMP-9 and MMP-2 proteins were examined by immunoblotting. Significantly increased levels of MMP-9 and MMP-2 proteins were detected in lung tissue from Balb/c mice that received B19V-VP1u or HBoV-VP1u than in that of mice that received PBS (Fig 2A). Fig 2B and 2C display ratios of MMP-9 and MMP-2 to β-actin, respectively.

Fig 1. Activity of MMP-9 and MMP-2 in lung tissue of Balb/c mice.

Fig 1

Open in a new tab

Activity of (A) MMP-9 and MMP-2 in lung tissue of Balb/c mice that received PBS, B19V-VP1u or HBoV-VP1u protein. Quantified results of (B) MMP-9, (C) MMP-2 and (D) ratio of MMP-9 to MMP-2. M is human serum and indicated as positive control. Similar results were observed in three repeated experiments, and * indicates a significant difference, P<0.05.

Fig 2. Expression of MMP9 and MMP2 proteins in lung tissue of Balb/c mice.

Fig 2

Open in a new tab

Expression of (A) MMP-9 and MMP-2 proteins in lung tissue of Balb/c mice that received PBS, B19V-VP1u or HBoV-VP1u protein. Bars represent the relative protein amounts of (B) MMP9 and (C) MMP2 on the basis of β-actin. M is human serum and indicated as positive control. Similar results were observed in three repeated experiments, and * indicates a significant difference, P<0.05.

B19V-VP1u and HBoV-VP1u proteins increase IL-1β and IL-6 expressions and lymphocyte infiltration in lung tissue of Balb/c mice

To investigate further whether B19V-VP1u and HBoV-VP1u cause lung injury in Balb/c mice, various inflammatory associated proteins, such as IL-1β and IL-6, were also examined. Significantly higher levels of IL-1β and IL-6 proteins were detected in lung tissue from Balb/c mice that received B19V-VP1u or HBoV-VP1u protein than in that from mice that received PBS (Fig 3A). Fig 3B and 3C show quantitative results concerning IL-1β and IL-6 proteins levels, respectively, relative to β-actin level. Hematoxylin and eosin staining was conducted to observe histopathological phenomena in lung tissue of Balb/c mice. Markedly greater lymphocyte infiltration was observed in lung tissue from Balb/c mice that received B19V-VP1u or HBoV-VP1u protein than in that from mice that received PBS (Fig 4). Fig 4B shows quantitative results.

Fig 3. Expression of cytokine proteins in lung tissue of Balb/c mice.

Fig 3

Open in a new tab

Expression of (A) IL-6 and IL-1β proteins in the lung tissue of Balb/c mice that received PBS, B19V-VP1u or HBoV-VP1u protein. Bars represent the relative protein amounts of (B) IL-6 and (C) IL-1β on the basis of β-actin. Similar results were observed in three repeated experiments, and * indicates a significant difference, P<0.05.

Fig 4. Lymphocyte infiltration in lung tissue of Balb/c mice.

Fig 4

Open in a new tab

Lung tissues from Balb/c mice that received PBS, B19V-VP1u or HBoV-VP1u protein were obtained and (A) sections of the lung tissue were stained with hematoxylin eosin. The images of lung tissue sections were magnified by 200 times. Amplified images are shown in the lower panel of each section. Lymphocyte infiltration is indicated by an arrow. (B) The number of infiltrated lymphocytes was calculated as described in the section of materials and methods. * indicates a significant difference, P<0.05.

Expression of NF-kB (p65), p-ERK, p-JNK and p-P38 in lung tissue of Balb/c mice received B19V-VP1u or HBoV-VP1u protein

To identify signaling molecules that may be involved in the activation of inflammatory cytokines, MMP-9 and MMP-2 in lung tissue of Balb/c mice that received B19V-VP1u or HBoV-VP1u protein, and the levels of NF-κB (p-p65), p-ERK1/2, p-p38, and p-JNK proteins were examined. Significantly increased expression of NF-κB (p-p65) protein was detected in lung tissue from Balb/c mice that received B19V-VP1u or HBoV-VP1u protein compared to that of mice that received PBS (Fig 5A). Fig 5B shows quantified results of NF-κB (p-p65) protein level relative to β-actin level. Furthermore, significantly increased expression of p-ERK1/2 proteins was detected in lung tissue from Balb/c mice that received HBoV-VP1u protein than in those of mice received PBS (Fig 6A). Significantly increased expression of p-p38 proteins was detected in lung tissue from Balb/c mice that received B19V-VP1u or HBoV-VP1u protein than in those of mice received PBS (Fig 6A). Significantly increased expression of p-JNK proteins was detected in lung tissue from Balb/c mice that received B19V-VP1u protein than in those of mice received PBS (Fig 6A). Fig 6B–6D display quantified results for levels of p-ERK1/2, p-p38 and p-JNK proteins, respectively, relative to β-actin level.

Fig 5. Expression of NF-kB (p65) protein in lung tissue of Balb/c mice.

Fig 5

Open in a new tab

Expression of NF-kB (p65) protein in lung tissue of Balb/c mice that received PBS, B19V-VP1u or HBoV-VP1u protein. Bars represent the relative protein amounts of (B) NF-kB (p65) on the basis of β-actin. Similar results were observed in three repeated experiments, and * indicates a significant difference, P<0.05.

Fig 6. Expression of MAPK proteins in lung tissue of Balb/c mice.

Fig 6

Open in a new tab

Expression of (A) p-ERK, p-P38 and p-JNK proteins in lung tissue of Balb/c mice that received PBS, B19V-VP1u or HBoV-VP1u protein. Bars represent the relative protein amounts of (B) p-ERK, (C) p-38, and (D) p-JNK on the basis of β-actin. Similar results were observed in three repeated experiments, and * indicates a significant difference, P<0.05.

Activity of MMP-9 and MMP-2 and expression of IL-1β and IL-6 in lung tissue of Balb/c mice received B19V-VP1uD175A or HBoV-VP1uL48R protein

To further confirm the role of sPLA2 activity within B19V-VP1u and HBoV-VP1u on lung injury, the activity of MMP-9 and MMP-2 and the expression of IL-6 and IL-1β in lung tissues of Balb/c mice received B19-VP1uD175A or HBoV-VP1uL48R protein was detected (Fig 7). No significant variation of MMP-9/MMP-2 ratio was observed in lung tissues of Balb/c mice received B19-VP1uD175A or HBoV-VP1uL48R protein as compared to those mice received PBS (Fig 7A). No significant variation was also detected in the expression of IL-6 and IL-1β proteins in lung tissues of Balb/c mice received B19-VP1uD175A or HBoV-VP1uL48R protein as compared to those mice received PBS (Fig 7B).

Fig 7. Activity of MMP-9 and MMP-2 and expression of IL-6 and IL-1β in lung tissue of Balb/c mice received mutated VP1u of B19V and HBoV.

Fig 7

Open in a new tab

Activity of (A) MMP-9 relative and MMP-2 in lung tissues of Balb/c mice received PBS, B19-VP1uD175A or HBoV-VP1uL48R protein. Lower panels reveal the ratio of MMP-9 activity relative to MMP-2 activity. Expression of (B) IL-6 and IL-1β proteins in lung tissues of Balb/c mice received PBS, B19-VP1uD175A or HBoV-VP1uL48R protein. Bars represent the relative protein amounts of IL-6 and IL-1β on the basis of β-actin. Similar results were observed in three repeated experiments, and * indicates the significant difference, P<0.05.

Discussion

Evidence from around the world suggests a connection between human parvoviruses, including B19V and HBoV, and numerous respiratory diseases [17–19,21,26–29]. Our recent study also revealed a disruptive effect of B19V-VP1u and HBoV-VP1u on tight junctions (TJs) in A549 lung cells [24]. However, no direct evidence of the involvement of human parvoviruses in lung injury has been reported. The current study is the first to reveal that B19V-VP1u and HBoV-VP1u induce lung inflammation in naïve mice following subcutaneous injection with recombinant B19V-VP1u or HBoV-VP1u proteins, including elevated activity and protein expressions of MMP-9 and MMP-2, increased levels of inflammatory cytokines such as IL-6 and IL-1β, and lymphocyte infiltration.

The matrix metalloproteinase (MMP) family of enzymes consist of 25 endopeptidases in mice and 24 in humans, which are known to be the enzymes most responsible for proteolytic degradation of the extracellular matrix (ECM) [30–31]. Matrix metalloproteinases (MMPs) have been involved in a variety of pathophysiological processes mainly tissue destruction, fibrosis and the weakening of ECM [32]. Dysregulation of ECM composition, structure, stiffness and abundance by MMPs contributes to several pathological conditions, including atherosclerosis, fibrosis and invasive cancer [33–35]. Several MMPs, such as MMP-2 and MMP-9, are important in lung remodeling before and after birth as well as in response to environmental indices, infection, and lung injury [35]. MMP-2 and MMP-9 are elevated under stress conditions such as acute respiratory infection and allergic inflammation, and have a protective role, involving the clearance of pathogens and the production of a chemotactic gradient [35–36]. Relevant studies also indicate that increased MMP-2 and MMP-9 levels are indices of lung injury and elevated levels of inflammatory cytokines, such as IL-6 and IL-1β [37]. In this study, similar observations of significantly increased activities and levels of MMP-9 and MMP-2 proteins and of inflammatory cytokines were made in the lung tissues of naïve mice that received B19V-VP1u or HBoV-VP1u, providing evidence that B19V-VP1u and HBoV-VP1u induce lung injury.

Previously obtained evidence has demonstrated that mitogen-activated protein kinases (MAPK), such as JNK, MAPK and p38 and transcription factors, such as nuclear factor-kappaB (NF-κB) and AP-1, have a fundamental role in the differential regulation of genes for proinflammatory mediators, including MMP-9, MMP-2, IL-6 and IL-1β [38–41]. A variety of studies have demonstrated the involvement of NF-κB and MAPK in response to various growth factors, inflammatory stimuli, and pro-oxidants and that these regulate the expression of gene products that are associated with inflammation, proliferation, invasion, and angiogenesis [42–43]. Different profile of MAPK signaling, including NF-κB (p-p65), p-ERK1/2 and p-p38 protein levels, was detected in lung tissue from Balb/c mice that received B19V-VP1u or HBoV-VP1u proteins. These findings suggest that B19V-VP1u and HBoV-VP1u can differentially regulate signaling pathways for inducing pro-inflammatory mediators in lung injury.

Various types of secretory PLA2 (sPLA2) are expressed in lung tissue and can cause acute lung injury, such as diffuse alveolar damage, bronchiolitis obliterans and organizing pneumonia pattern [44–46]. Additionally, macrophages in the lung can secrete PLA2, which induces enzymes such as MMP and inflammatory cytokines such as IL-6 and IL-1β, resulting in lung inflammation [47]. The sPLA2-like activity of B19V-VP1u and HBoV-VP1u has also been linked to a wide range of pathogenic responses, including autoimmune disorders, cardiovascular disorders and respiratory infection [17,48]. Indeed, evidence has indicated that the unique region of VP1 in B19V and HBoV plays a crucial role in infection and induce inflammation in host cells or tissues due to its phospholipase A2 (PLA2)-like activity [14–16,48–50]. Although previous studies have reported that B19-VP1u protein induces myocardial inflammation and liver injury in naïve mice [48–49], little is known whether HBoV-VP1u affect the other organs in mice receiving HBoV-VP1u protein. In the current investigation, similar observations were made in naïve mice that received B19V-VP1u or HBoV-VP1u, which exhibit elevated MMP-9 and MMP-2 activity, and a markedly elevated level of inflammatory cytokines and considerable lymphocyte infiltration in lung tissues. Since the epithelia in the airway tract are vulnerable to sPLA2 owing to its proteolytic activity [51], these findings suggest the involvement of B19V-VP1u and HBoV-VP1u in inducing lung injury through sPLA2 activity. Notably, the current study further revealed that B19-VP1uD175A or HBoV-VP1uL48R has no significant effect on increasing lung MMP-9/MMP-2 ratio and expression of IL-6 and IL-1β proteins, suggesting an essential role of sPLA2 activity within B19V-VP1u and HBoV-VP1u on inducing lung injury.

Conclusions

This study is the first to demonstrate the induction of lung injury by both B19V-VP1u and HBoV-VP1u in naïve mice by elevating MMP9/2 activation, proinflammation cytokine expression, and lymphocyte infiltration in lung tissue through differentially regulating NF-κB and MAPK signaling pathways.

Acknowledgments

This study was supported by the Chung Shan Medical University under Grant [CSMU-INT-102-01]; Chung Shan Medical University and Chi-Mei Medical Center cooperative project under Grant [CSMU-CMMC-104-02]; and Ministry of Science and Technology under Grant [MOST-106-2314-B040-023], Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Data Availability

All relevant data are within the manuscript.

Funding Statement

This study was supported by the Chung Shan Medical University under Grant [CSMU-INT-102-01]; Chung Shan Medical University and Chi-Mei Medical Center cooperative project under Grant [CSMU-CMMC-104-02]; and Ministry of Science and Technology under Grant [MOST-106-2314- B040-023], Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Britto CJ, Brady V, Lee S, Dela Cruz CS. Respiratory Viral Infections in Chronic Lung Diseases. Clin Chest Med. 2017;38:87–96. 10.1016/j.ccm.2016.11.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Tan WC, Xiang X, Qiu D, Nq TP, Lam SF, Heqele RG. Epidemiology of respiratory viruses in patients hospitalized with near-fatal asthma, acute exacerbations of asthma, or chronic obstructive pulmonary disease. Am J Med. 2003;115:272–277. [DOI] [PubMed] [Google Scholar]
  • 3.Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000;161:1501–1507. 10.1164/ajrccm.161.5.9906076 [DOI] [PubMed] [Google Scholar]
  • 4.Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbergsson F, Bjarnason R, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax. 2010; 65:1045–1052. 10.1136/thx.2009.121582 [DOI] [PubMed] [Google Scholar]
  • 5.Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med. 2008;178:667–672. 10.1164/rccm.200802-309OC [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Abman SH, Ogle JW, Harbeck RJ, Butler-Simon N, Hammond KB, Accurso FJ. Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening. J Pediatr 1991;119:211–217. [DOI] [PubMed] [Google Scholar]
  • 7.Wat D, Gelder C, Hibbitts S, Cafferty F, Bowler I, Pierrepoint M, et al. The role of respiratory viruses in cystic fibrosis. J Cyst Fibros. 2008;7:320–328. 10.1016/j.jcf.2007.12.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Nash EF, Whitmill R, Barker B, Rashid R, Whitehouse JL, Honeybourne D. Clinical outcomes of pandemic (H1N1) 2009 influenza (swine flu) in adults with cystic fibrosis. Thorax. 2011;66:259. [DOI] [PubMed] [Google Scholar]
  • 9.Colombo C, Battezzati PM, Lucidi V, Magazzù G, Motta V, Alicandro G, et al. Influenza A/H1N1 in patients with cystic fibrosis in Italy: a multicentre cohort study. Thorax. 2011;66:260–261. 10.1136/thx.2010.157032 [DOI] [PubMed] [Google Scholar]
  • 10.Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004;350:586–597. 10.1056/NEJMra030840 [DOI] [PubMed] [Google Scholar]
  • 11.Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, et al. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci USA 2005;102:12891–12896. 10.1073/pnas.0504666102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Broliden K, Tolfvenstam T, Norbeck O. Clinical aspects of parvovirus B19 infection. J Intern Med 2006;260:285–304. 10.1111/j.1365-2796.2006.01697.x [DOI] [PubMed] [Google Scholar]
  • 13.Kerr JR. The role of parvovirus B19 in the pathogenesis of autoimmunity and autoimmune disease. J Clin Pathol. 2016;69:279–291. 10.1136/jclinpath-2015-203455 [DOI] [PubMed] [Google Scholar]
  • 14.Dorsch S, Liebisch G, Kaufmann B, von Landenberg P, Hoffmann JH, Drobnik W, et al. The VP1 unique region of parvovirus B19V and its constituent phospholipase A2-like activity. J Virol 2002;76:2014–2018. 10.1128/JVI.76.4.2014-2018.2002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Meyer O. Parvovirus B19 and autoimmune diseases. Joint Bone Spine. 2003;70:6–11. [DOI] [PubMed] [Google Scholar]
  • 16.Costa C, Terlizzi ME, Solidoro P, Libertucci D, Bergallo M, Cavallo R. Detection of parvovirus B19 in the lower respiratory tract. J Clin Virol 2009;46:150–153. 10.1016/j.jcv.2009.06.026 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Wiersbitzky S, Schwarz TF, Bruns R, Ballke EH, Wiersbitzky H, Jäger G, et al. Obstructive respiratory tract diseases in children and Parvovirus B19 infections. Kinderarztl Prax. 1991;59:299–301. [PubMed] [Google Scholar]
  • 18.Maggi F, Andreoli E, Pifferi M, Meschi S, Rocchi J, Bendinelli M. Human bocavirus in Italian patients with respiratory diseases. J Clin Virol. 2007;38:321–325. 10.1016/j.jcv.2007.01.008 [DOI] [PubMed] [Google Scholar]
  • 19.Zhang LL, Tang LY, Xie ZD, Tan XJ, Li CS, Cui AL, et al. Human bocavirus in children suffering from acute lower respiratory tract infection in Beijing Children's Hospital. Chin Med J (Engl). 2008;121:1607–1610. [PubMed] [Google Scholar]
  • 20.Zeng M, Zhu QR, Wang XH, Yu H, Shen J. Human bocavirus in children with respiratory tract infection in Shanghai: a retrospective study. World J Pediatr 2010;6: 65–70. 10.1007/s12519-010-0009-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Chuang CY, Kao CL, Huang LM, Lu CY, Shao PL, Lee PI, et al. Human bocavirus as an important cause of respiratory tract infection in Taiwanese children. J Microbiol Immunol Infect. 2011;44:323–327. 10.1016/j.jmii.2011.01.036 [DOI] [PubMed] [Google Scholar]
  • 22.Bousvaros A, Sundel R, Thorne GM, McIntosh K, Cohen M, Erdman DD, et al. Parvovirus B19-associated interstitial lung disease, hepatitis, and myositis. Pediatr Pulmonol. 1998;26:365–369. [DOI] [PubMed] [Google Scholar]
  • 23.Ricour C, Goubau P. Human bocavirus, a newly discovered parvovirus of the respiratory tract. Acta Clin Belg. 2008;63:329–334. 10.1179/acb.2008.064 [DOI] [PubMed] [Google Scholar]
  • 24.Chiu CC, Shi YF, Yang JJ, Hsiao YC, Tzang BS, Hsu TC. Effects of human parvovirus B19 and Bocavirus VP1 unique region on tight junction of human airway epithelial A549 cells. PLoS ONE 2014;9:e107970 10.1371/journal.pone.0107970 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Tzang BS, Tsay GJ, Lee YJ, Li C, Sun YS, Hsu TC. The association of VP1 unique region protein in acute parvovirus B19 infection and antiphospholipid antibody production. Clin Chim Acta 2007;378:59–65. 10.1016/j.cca.2006.10.016 [DOI] [PubMed] [Google Scholar]
  • 26.Qu XW, Liu WP, Qi ZY, Duan ZJ, Zheng LS, Kuang ZZ et al. Phospholipase A2-like activity of human bocavirus VP1 unique region. Biochem Biophys Res Commun 2008;365:158–163. 10.1016/j.bbrc.2007.10.164 [DOI] [PubMed] [Google Scholar]
  • 27.Tzang BS, Lin TM, Tsai CC, Hsu JD, Yang LC, Hsu TC. Increased cardiac injury in NZB/W F1 mice received antibody against human parvovirus B19 VP1 unique region protein. Mol Immuno 2011;48:1518–1524. [DOI] [PubMed] [Google Scholar]
  • 28.von Linstow ML, Hogh M, Hogh B. Clinical and epidemiologic characteristics of human bocavirus in Danish infants: results from a prospective birth cohort study. Pediatr Infect Dis J. 2008;27:897–902. 10.1097/INF.0b013e3181757b16 [DOI] [PubMed] [Google Scholar]
  • 29.Etemadi MR, Jalilian FA, Abd Wahab N, Jhanshiri F, Amini R, Othman N, et al. First detected human bocavirus in a Malaysian child with pneumonia and pre-existing asthma: a case report. Med J Malaysia. 2012;67:433–434. [PubMed] [Google Scholar]
  • 30.Puente XS, Sanchez LM, Overall CM, López-Otín C. Human and mouse proteases: a comparative genomic approach. Nat Rev Genet. 2003;4:544–558. 10.1038/nrg1111 [DOI] [PubMed] [Google Scholar]
  • 31.Greenlee KJ, Werb Z, Kheradmand F. Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted. Physiol Rev. 2007;87:69–98. 10.1152/physrev.00022.2006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Amălinei C, Căruntu ID, Giuşcă SE, Bălan RA. Matrix metalloproteinases involvement in pathologic conditions. Rom J Morphol Embryol. 2010;51:215–228. [PubMed] [Google Scholar]
  • 33.Lin J, Kakkar V, Lu X. Impact of matrix metalloproteinases on atherosclerosis. Curr Drug Targets. 2014;15:442–453. [DOI] [PubMed] [Google Scholar]
  • 34.Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014;15:786–801. 10.1038/nrm3904 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Hendrix AY, Kheradmand F. The Role of Matrix Metalloproteinases in Development, Repair, and Destruction of the Lungs. Prog Mol Biol Transl Sci. 2017;148:1–29. 10.1016/bs.pmbts.2017.04.004 [DOI] [PubMed] [Google Scholar]
  • 36.Atkinson JJ, Senior RM. Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol. 2003;28:12–24. 10.1165/rcmb.2002-0166TR [DOI] [PubMed] [Google Scholar]
  • 37.Kotecha S. Cytokines in chronic lung disease of prematurity. Eur J Pediatr. 1996; 155:S14–17. [DOI] [PubMed] [Google Scholar]
  • 38.Rahman I, MacNee W. Regulation of redox glutathione levels and gene transcription in lung inflammation: therapeutic approaches. Free Radic Biol Med. 2000;28:1405–1420. [DOI] [PubMed] [Google Scholar]
  • 39.Watanabe T, Jono H, Han J, Lim DJ, Li JD. Synergistic activation of NF-kappaB by nontypeable Haemophilus influenzae and tumor necrosis factor alpha. Proc Natl Acad Sci U S A. 2004;101:3563–3568. 10.1073/pnas.0400557101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Lee SH, Lee YJ, Han HJ. Effect of arachidonic acid on hypoxia-induced IL-6 p roduction in mouse ES cells: Involvement of MAPKs, NF-kappaB, and HIF-1alpha. J Cell Physiol. 2010;222:574–585. 10.1002/jcp.21973 [DOI] [PubMed] [Google Scholar]
  • 41.Morin C, Hiram R, Rousseau E, Blier PU, Fortin S. Docosapentaenoic acid monoacylglyceride reduces inflammation and vascular remodeling in experimental pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2014;307:H574–586. 10.1152/ajpheart.00814.2013 [DOI] [PubMed] [Google Scholar]
  • 42.Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002;3:221–227. 10.1038/ni0302-221 [DOI] [PubMed] [Google Scholar]
  • 43.Yang CM, Hsieh HL, Lee CW. Intracellular signaling mechanisms underlying the expression of pro-inflammatory mediators in airway diseases. Chang Gung Med J. 2005;28:813–823. [PubMed] [Google Scholar]
  • 44.Attalah HL, Wu Y, Alaoui-El-Azher M, Thouron F, Koumanov K, Wolf C, et al. Induction of type-IIA secretory phospholipase A2 in animal models of acute lung injury. Eur Respir J 2003;21:1040–1045. [DOI] [PubMed] [Google Scholar]
  • 45.Chen HL, Hai CX, Liang X, Zhang XD, Liu R, Qin XJ. Correlation between sPLA2-IIA and phosgene-induced rat acute lung injury. Inhal Toxicol 2009;21:374–380. 10.1080/08958370802449712 [DOI] [PubMed] [Google Scholar]
  • 46.Kawabata K, Fujioka D, Kobayashi T, Saito Y, Obata JE, Nakamura T, et al. Inhibition of secretory phospholipase A2 activity attenuates acute cardiogenic pulmonary edema induced by isoproterenol infusion in mice after myocardial infarction. J Cardiovasc Pharmacol 2010;56:369–378. 10.1097/FJC.0b013e3181ef1aab [DOI] [PubMed] [Google Scholar]
  • 47.Triggiani M, Granata F, Oriente A, De Marino V, Gentile M, Calabrese C, et al. Secretory phospholipases A2 induce beta-glucuronidase release and IL-6 production from human lung macrophages. J Immunol 2000;164:4908–4915. [DOI] [PubMed] [Google Scholar]
  • 48.Hsu TC, Chiu CC, Chang SC, Chan HC, Shi YF, Chen TY, et al. Human parvovirus B19V VP1u Protein as inflammatory mediators induces liver injury in naïve mice. Virulence 2016;7:110–118. 10.1080/21505594.2015.1122165 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Nie X, Zhang G, Xu D, Sun X, Li Z, Li X, et al. The VP1-unique region of parvovirus B19 induces myocardial injury in mice. Scand J Infect Dis.2010;42:121–128. 10.3109/00365540903321580 [DOI] [PubMed] [Google Scholar]
  • 50.Lin CY, Chiu CC, Cheng J, Lin CY, Shi YF, Tsai CC, et al. Antigenicity analysis of human parvovirus B19V-VP1u protein in the induction of anti-phospholipid syndrome. Virulence 2018;9:208–216. 10.1080/21505594.2017.1385691 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Turner JR. Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am J Pathol 2006;169:1901–1909. 10.2353/ajpath.2006.060681 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

All relevant data are within the manuscript.

Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES